↓ Skip to main content

Developing and financing neglected disease vaccines in our new era of “blue marble health” and the anthropocene epoch

Overview of attention for article published in Vaccine, September 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

news
1 news outlet
twitter
5 tweeters

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
28 Mendeley
Title
Developing and financing neglected disease vaccines in our new era of “blue marble health” and the anthropocene epoch
Published in
Vaccine, September 2017
DOI 10.1016/j.vaccine.2017.02.002
Pubmed ID
Authors

Peter J. Hotez

Abstract

New findings of widespread neglected diseases among the poor living in wealthy group of 20 (G20) economies and the concept of "blue marble health" offer innovative mechanisms for financing urgently new vaccines, especially for vector-borne neglected tropical diseases (NTDs). This approach could complement or parallel a recently suggested global vaccine development fund for pandemic threats.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 28 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 29%
Student > Ph. D. Student 4 14%
Student > Master 4 14%
Student > Bachelor 3 11%
Librarian 1 4%
Other 3 11%
Unknown 5 18%
Readers by discipline Count As %
Medicine and Dentistry 4 14%
Agricultural and Biological Sciences 4 14%
Immunology and Microbiology 3 11%
Social Sciences 2 7%
Economics, Econometrics and Finance 2 7%
Other 6 21%
Unknown 7 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 March 2020.
All research outputs
#1,461,070
of 15,339,977 outputs
Outputs from Vaccine
#1,119
of 12,568 outputs
Outputs of similar age
#39,441
of 260,261 outputs
Outputs of similar age from Vaccine
#40
of 197 outputs
Altmetric has tracked 15,339,977 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,568 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 260,261 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 197 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.